Lyophilised protein formulations as a patient-centric dosage form: A contribution toward sustainability paradigm
Pubblicato online: 30 mag 2024
Pagine: 289 - 300
Accettato: 08 gen 2024
DOI: https://doi.org/10.2478/acph-2024-0013
Parole chiave
© 2024 Maja Bjelošević Žiberna et al., published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
At present, society has embraced the fact apropos population aging and climate changes, that demand, amongst others, innovative pharmaceutical technologies, emphasising the development of patient-specific delivery systems and thus the provision of efficient and sustainable drugs. Protein drugs for subcutaneous administration, by allowing less frequent application, represent one of the most important parts of the pharmaceutical field, but their development is inevitably faced with obstacles in providing protein stability and suitable formulation viscosity. To gain further knowledge and fill the gaps in the already constructed data platform for the development of monoclonal antibody formulations, we designed a study that examines small model proteins,